Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.